Conjugate Vaccine Global Market Report 2024

Description

“Conjugate Vaccine Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on conjugate vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for conjugate vaccine? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The conjugate vaccine market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Product Type: Monovalent Conjugate Vaccines; Multivalent Conjugate Vaccine
2) By Pathogen: Bacterial; Viral
3) By Disease Indication: Pneumococcal; Influenza; Meningococcal; Typhoid
4) By Patient: Pediatric; Adults
5) By End-User: Hospitals; Clinics; Homecare Settings; Other End Users
Companies Mentioned: Sanofi S.A.; Pfizer Inc.; Merck & Co. Inc.; GlaxoSmithKline plc; Bharat Biotech International Limited
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Conjugate vaccines, also referred to as immunogen conjugates, represent advanced immune system modulators extensively employed to induce protection against invading pathogens or stimulate specific antibodies against a targeted molecule. The conjugation process plays a crucial role in augmenting the immune response, enabling a more effective recognition of the pathogen by the immune system.

Two primary types of conjugate vaccines are monovalent conjugate vaccines and multivalent conjugate vaccines. Monovalent conjugate vaccines consist of a single conjugated antigen, typically designed to target a specific pathogen or strain. These vaccines are utilized for preventing infections caused by bacteria with a polysaccharide capsule, such as streptococcus pneumoniae, haemophilus influenzae type B, and neisseria meningitidis. Monovalent conjugate vaccines are developed to address various diseases, including pneumococcal, influenza, meningococcal, and typhoid. They find application in pediatric and adult patient populations and are utilized in diverse healthcare settings such as hospitals, clinics, homecare, and other medical facilities.

The conjugate vaccine research report is one of a series of new reports from The Business Research Company that provides conjugate vaccine market statistics, including the conjugate vaccine industry's global market size, regional shares, competitors with a conjugate vaccine market share, detailed conjugate vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the conjugate vaccine industry. This conjugate vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The conjugate vaccine market size has grown rapidly in recent years. It will grow from $16.77 billion in 2023 to $19.11 billion in 2024 at a compound annual growth rate (CAGR) of 13.9%. The expansion observed in the historical period can be attributed to several factors, including the burden of diseases, government-driven immunization programs, heightened awareness regarding vaccination, a focus on pediatric vaccination, and the prevailing trends in preventive healthcare.

The conjugate vaccine market size is expected to see rapid growth in the next few years. It will grow to $30.65 billion in 2028 at a compound annual growth rate (CAGR) of 12.5%. The anticipated growth in the forecasted period can be attributed to a range of factors, including the expansion of immunization policies, the dynamics of an aging population, the emergence of new vaccine indications, heightened global health security concerns, international collaboration efforts, and the impact of economic development. Noteworthy trends expected in this period include increased collaborations and partnerships for efficient vaccine distribution, tailored approaches targeting high-risk populations, the application of vaccines in emerging infectious diseases, advancements in vaccine manufacturing technologies, and global health initiatives focused on achieving vaccine equity.

The anticipated growth in the conjugate vaccine market is driven by the increasing utilization of these vaccines among adults. Conjugate vaccines are specifically formulated to elicit a robust immune response against bacterial capsular polysaccharides, fortifying the body's defenses against bacterial infections. Their application in the adult population serves to mitigate the risk of severe illness, complications, and the transmission of bacterial diseases by bolstering the immune response. As evidenced by the Historical National Influenza Vaccination Coverage report spanning 2020-2022 from the National Centre for Immunization Research and Surveillance, vaccination coverage for the 15 - < 50 years age group reached 29.5% at the end of 2022, showcasing a notable increase from the 22.8% recorded in 2021. This upsurge in the use of conjugate vaccines for adults is a significant driver of the growth in the conjugate vaccine market.

The projected expansion of the conjugate vaccine market is underpinned by the rising incidence of infectious diseases. Infectious diseases, caused by pathogenic microorganisms such as bacteria, viruses, parasites, or fungi, pose significant public health challenges. Conjugate vaccines play a pivotal role in preventing infectious diseases, particularly those caused by specific bacteria, and are especially crucial for vulnerable populations such as infants and young children. According to the Pan American Health Organization's data from October 2022, approximately 10.6 million individuals contracted tuberculosis (TB) in 2021, marking a 4.5% increase from 2020. Among those affected, 1.6 million individuals succumbed to TB, including 187,000 cases among people living with HIV. This escalating incidence of infectious diseases is a key factor propelling the growth of the conjugate vaccine market.

Innovation in conjugate vaccines emerges as a prominent trend gaining traction in the conjugate vaccine market. Companies actively involved in this market are strategically focused on the development of innovative conjugate vaccines to maintain their competitive standing. An exemplar of this trend is Pfizer Inc., a US-based pharmaceutical and biotechnology company, which, in June 2022, launched Prevnar 20, a pneumococcal 20-valent conjugate vaccine, in Canada. This vaccine is designed to prevent pneumonia and invasive pneumococcal infections in adults aged 18 and older. Prevnar 20 includes conjugates for the 13 serotypes covered by PREVNAR 13, along with conjugates for seven additional serotypes associated with invasive pneumococcal disease, characterized by high case-fatality rates, antibiotic resistance, and meningitis.

Major companies operating in the conjugate vaccine market are directing their efforts towards the development of advanced conjugate vaccines, including the 21-valent pneumococcal conjugate vaccine. This type of vaccine is crafted to provide protection against infections caused by Streptococcus pneumoniae bacteria. An illustrative example is Merck & Co., Inc., a US-based pharmaceutical company, which, in April 2022, received the Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for its 'V116.' V116 is a 21-valent pneumococcal conjugate vaccine designed for the prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia. Tailored to target strains of pneumococcal bacteria commonly found in adults, V116 represents a significant advancement in conjugate vaccine development.

In August 2022, GSK, a UK-based pharmaceutical and biotechnology company, completed the acquisition of Affinivax Inc. for $2.1 billion. This strategic move by GSK is aimed at fortifying its portfolio of specialty medicines and vaccines, particularly in the realm of advanced pneumococcal vaccines. The acquisition includes Affinivax's AFX3772, contributing to GSK's position in the development of cutting-edge conjugate vaccines. Affinivax, a US-based biotechnology company, specializes in the development of conjugate vaccines.

Major companies operating in the conjugate vaccine market report are Sanofi S.A., Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute of India Private Limited, Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., Bio-Med Pvt. Ltd., AstraZeneca plc, Johnson & Johnson, Moderna Inc., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Inovio Pharmaceuticals Inc., Medicago Inc., Mitsubishi Tanabe Pharma Corporation, Panacea Biotec Ltd., Protein Sciences Corporation, Seqirus

North America was the largest region in the global conjugate vaccine market in 2023. The regions covered in the conjugate vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the conjugate vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The conjugate vaccine market consists of sales of diphtheria, tetanus, and pertussis (DTaP) conjugate vaccine, haemophilus influenza type b (Hib) conjugate vaccine, and E. coli conjugate vaccine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r11637

1. Executive Summary

2. Conjugate Vaccine Market Characteristics

3. Conjugate Vaccine Market Trends And Strategies

4. Conjugate Vaccine Market - Macro Economic Scenario

4.1. Impact Of High Inflation On the Market
4.2. Ukraine-Russia War Impact On the Market
4.3. COVID-19 Impact On the Market

5. Global Conjugate Vaccine Market Size and Growth

5.1. Global Conjugate Vaccine Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Conjugate Vaccine Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Conjugate Vaccine Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Conjugate Vaccine Market Segmentation

6.1. Global Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Monovalent Conjugate Vaccines
Multivalent Conjugate Vaccine
6.2. Global Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Bacterial
Viral
6.3. Global Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Pneumococcal
Influenza
Meningococcal
Typhoid
6.4. Global Conjugate Vaccine Market, Segmentation By Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Pediatric
Adults
6.5. Global Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Clinics
Homecare Settings
Other End Users

7. Conjugate Vaccine Market Regional And Country Analysis

7.1. Global Conjugate Vaccine Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Conjugate Vaccine Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Conjugate Vaccine Market

8.1. Asia-Pacific Conjugate Vaccine Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Conjugate Vaccine Market

9.1. China Conjugate Vaccine Market Overview
9.2. China Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Conjugate Vaccine Market

10.1. India Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Conjugate Vaccine Market

11.1. Japan Conjugate Vaccine Market Overview
11.2. Japan Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Conjugate Vaccine Market

12.1. Australia Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Conjugate Vaccine Market

13.1. Indonesia Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Conjugate Vaccine Market

14.1. South Korea Conjugate Vaccine Market Overview
14.2. South Korea Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Conjugate Vaccine Market

15.1. Western Europe Conjugate Vaccine Market Overview
15.2. Western Europe Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Conjugate Vaccine Market

16.1. UK Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Conjugate Vaccine Market

17.1. Germany Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Conjugate Vaccine Market

18.1. France Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Conjugate Vaccine Market

19.1. Italy Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Conjugate Vaccine Market

20.1. Spain Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Conjugate Vaccine Market

21.1. Eastern Europe Conjugate Vaccine Market Overview
21.2. Eastern Europe Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Conjugate Vaccine Market

22.1. Russia Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Conjugate Vaccine Market

23.1. North America Conjugate Vaccine Market Overview
23.2. North America Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Conjugate Vaccine Market

24.1. USA Conjugate Vaccine Market Overview
24.2. USA Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Conjugate Vaccine Market

25.1. Canada Conjugate Vaccine Market Overview
25.2. Canada Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Conjugate Vaccine Market

26.1. South America Conjugate Vaccine Market Overview
26.2. South America Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Conjugate Vaccine Market

27.1. Brazil Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Conjugate Vaccine Market

28.1. Middle East Conjugate Vaccine Market Overview
28.2. Middle East Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Conjugate Vaccine Market

29.1. Africa Conjugate Vaccine Market Overview
29.2. Africa Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Conjugate Vaccine Market Competitive Landscape And Company Profiles

30.1. Conjugate Vaccine Market Competitive Landscape
30.2. Conjugate Vaccine Market Company Profiles
- 30.2.1. Sanofi S.A.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Pfizer Inc.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Merck & Co. Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. GlaxoSmithKline plc
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Bharat Biotech International Limited
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Global Conjugate Vaccine Market Competitive Benchmarking

32. Global Conjugate Vaccine Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Conjugate Vaccine Market

34. Conjugate Vaccine Market Future Outlook and Potential Analysis

34.1 Conjugate Vaccine Market In 2028 - Countries Offering Most New Opportunities
34.2 Conjugate Vaccine Market In 2028 - Segments Offering Most New Opportunities
34.3 Conjugate Vaccine Market In 2028 - Growth Strategies
- 34.3.1 Market Trend Based Strategies
- 34.3.2 Competitor Strategies

35. Appendix

35.1. Abbreviations
35.2. Currencies
35.3. Historic And Forecast Inflation Rates
35.4. Research Inquiries
35.5. The Business Research Company
35.6. Copyright And Disclaimer